AdvaMed President and CEO Releases Statement On the House Bill To Repeal the Medical Device Tax

Thursday, April 11, 2019

WASHINGTON, D.C. – Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed), issued the following statement on introduction of bipartisan legislation (H.R. 2207) in the U.S. House of Representatives to permanently repeal the medical device excise tax:

“America’s medical technology industry is facing a $20 billion tax increase at year-end, when the current medical device tax suspension expires. Urgent action is essential to protect future medtech innovations that benefit patients and to avoid putting good-paying U.S. jobs at risk.

“House introduction today of the ‘Protect Medical Innovation Act of 2019’ in the 116th Congress brings us one step closer to ensuring this innovation-stifling burden on the medtech industry never returns, supporting continued American leadership of this vital industry.

“We thank the bill’s lead sponsors, Reps. Ron Kind (D-Wis.), Jackie Walorski (R-Ind.), Scott Peters (D-Calif.), and Richard Hudson (R-N.C.) for their leadership on this issue. This bill – and the strong bipartisan support they have gathered – reflect the high priority this Congress places on patients, jobs, and future investment.

“While past suspensions of the medical device tax have enabled manufacturers to invest in R&D, infrastructure and new hiring – which in turn benefits patients and the U.S. economy – these benefits are at risk. Now that bipartisan legislation to permanently repeal the device tax has been introduced in both the House and Senate, AdvaMed will urge Congress and the administration to act as expeditiously as possible to get rid of the tax once and for all this year.”

Continue Reading

Inscripta Completes $20M Expansion of Series C Financing, Increasing Total Round to $105.5M

Monday, April 08, 2019

Inscripta, a leading gene editing technology company, today announced that it has increased its previously announced Series C financing with an additional $20 million from existing investors. The new funding adds to the $85.5 million financing Inscripta announced in 2018, bringing the total raised for the round to $105.5 million. 

Weekly Policy Update: Drug Pricing Transparency Bill Introduced in Colorado, Plus CBSA Advocates in DC

Friday, April 05, 2019


CBSA and BIO Honor Colorado Congressional Leaders as Innovators in Biotechnology

Thursday, April 04, 2019

Senator Michael Bennet, Congresswoman Diana DeGette Recognized as Champions of Life Science 
Continue Reading

Colorado BioScience Association Applauds Expansion by Novartis Company AveXis to Longmont

Monday, April 01, 2019

April 1, 2019

Weekly Policy Update: CBSA Raises Concerns about Importing Drugs From Canada, Plus A Full Review of this Month In Policy

Friday, March 29, 2019

This week President & CEO Jennifer Jones Paton spoke with 630 KHOW’s Krista Kafer about CBSA’s opposition to Senate Bill 5, which would create a Canadian drug importation program in Colorado. Throughout the conversation Jennifer explained that the innovators CBSA represents are dedicated to developing new treatments and cures and ensuring patients have access to those medicines, but this legislation would jeopardize patient safety and do little to reduce prescription drug costs.  

Weekly Policy Update: Colorado State Budget and Forecast, Plus CBSA Voices Concerns on Drug Pricing Legislation

Friday, March 22, 2019


Weekly Policy Update: Family Medical Leave Insurance Program and the President's Proposed Budget

Friday, March 15, 2019

On Wednesday Senate Bill 188, FAMLI Family Medical Leave Insurance Program, was heard and passed out of the Senate Committee on Business, Labor & Technology. The bill would create a state-run family and medical leave insurance program to provide partial wage replacement benefits to an eligible individual who takes leave from work:  

Weekly Policy Update: Colorado BioScience Association’s Annual Day at the Capitol

Friday, March 08, 2019


Colorado BioScience Association Explores New Possibilities for Medtech at Annual Symposium

Monday, March 04, 2019

Medical device industry leaders to focus on blockchain technology, M&A trends and federal policy 
Continue Reading